SELB stock forecast
Our latest prediction for Selecta Biosciences, Inc.'s stock price was made on the Aug. 14, 2019 when the stock price was at 1.70$.
In the short term (2weeks), SELB's stock price should outperform the market by 7.14%. During that period the price should oscillate between -8.87% and +18.44%.
In the medium term (3months), SELB's stock price should outperform the market by 14.08%. During that period the price should oscillate between -21.01% and +55.45%.Get email alerts
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -2.04$ per share.
The book value per share is 1.08$
Three months stock forecastAug. 14, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|